1. Home
  2. SN vs IONS Comparison

SN vs IONS Comparison

Compare SN & IONS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SharkNinja Inc.

SN

SharkNinja Inc.

HOLD

Current Price

$124.12

Market Cap

15.9B

Sector

N/A

ML Signal

HOLD

Logo Ionis Pharmaceuticals Inc.

IONS

Ionis Pharmaceuticals Inc.

HOLD

Current Price

$84.58

Market Cap

13.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SN
IONS
Founded
1993
1989
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
15.9B
13.5B
IPO Year
2023
1996

Fundamental Metrics

Financial Performance
Metric
SN
IONS
Price
$124.12
$84.58
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
8
22
Target Price
$132.88
$84.09
AVG Volume (30 Days)
1.5M
1.7M
Earning Date
01-01-0001
04-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.70
Revenue
N/A
N/A
Revenue This Year
$15.19
$29.86
Revenue Next Year
$10.81
$0.53
P/E Ratio
$25.86
$118.79
Revenue Growth
N/A
N/A
52 Week Low
$60.50
$23.95
52 Week High
$133.99
$86.74

Technical Indicators

Market Signals
Indicator
SN
IONS
Relative Strength Index (RSI) 52.09 57.72
Support Level $111.44 $75.66
Resistance Level $128.85 $86.45
Average True Range (ATR) 6.33 2.59
MACD 0.32 -0.12
Stochastic Oscillator 53.80 69.40

Price Performance

Historical Comparison
SN
IONS

About SN SharkNinja Inc.

SharkNinja Inc is a product design and technology company that creates 5-star-rated lifestyle solutions through inventive products for consumers around the world. Its product categories include Cleaning, Cooking, Food Preparation, Home Environment and Beauty products. It sells vacuum cleaners, cooking pots, fryers, hair dryers, etc. The SharkNinja Group is expected to carry on the design, production, marketing, and distribution of the Shark and Ninja brands of small household appliances in North America, Europe and other selected international markets (excluding the Asia Pacific Region and Greater China). Currently, the majority of the revenue is derived from the U.S. market.

About IONS Ionis Pharmaceuticals Inc.

Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.

Share on Social Networks: